Page Menu

Business of Biotech 2021

Leading Growth and Change – Together

The Business of Biotech Conference will be virtual in 2021. The 15th annual conference will be held March 25 and 26.

Keynote speakers: Moffitt President and CEO Dr. Patrick Hwu and Executive Vice-President and Center Director Dr. John Cleveland.

Registration to open by the end of February. Please check back for further updates. To receive conference updates, email Innovation@Moffitt.org

BREAKOUT SESSIONS

Paving the Way: Partnerships Stimulate novel Cell Therapies

With two approved therapies and close to 650 clinical / preclinical product candidates, the T cell immunotherapy pipeline has evolved significantly over the past few years. According to a 2019 report prepared by Roots Analysis, many investors have invested “over USD 13 billion, across 200+ instances, in the period between 2000 and 2019, having realized the opportunity within this upcoming segment of cancer immunotherapy”. This panel will discuss how novel therapy development efforts are anticipated to drive partnership activity and particularly the vital role academic organizations play in these new initiatives.

 

Clinical Research: Advancing New Treatments Through Collaboration

Targeted therapies and emerging diagnostics are the foundation for precision medicine that allows us to untangle the web of cancer care on a molecular level. Clinical trials are critical in moving these technologies to market, however these are informed by translational research at that validates new targets and novel compounds. Interdisciplinary research between industry and academic partners has therefore proven to be an indispensable tool in advancing these treatments from bench to bedside. Panelists join this session to discuss the future of targeted therapies, common hurdles, and the role of collaboration in the development process.

 

Transitioning from Concept to Clinic: Conversations About Moving from Bench Asset to First Patient Dosing

Oncology discovery is growing at an exponential rate with treatments continuing to grow in complexity; from IO to Cellular Therapies. The challenge is that every new idea at the bench needs a path to the patient. With a number of challenges ranging from regulatory procedures to manufacturing scale-up, OncoBay is uniquely situated to help bring these concepts into the clinic. Founded in 2019, this boutique immuno-oncology CRO specializes in providing customized, end-to-end solutions for drug developers seeking to operationalize discovery. Experts join this panel to discuss this process, and provide insight on how to best leverage an experienced CRO partner to accelerate development and decision making.

 

Artificial Intelligence: Forging New Frontiers to Improve Healthcare Delivery and Management

Recent events over the past few years have had a major impact on the healthcare industry overall, creating new demand for artificial intelligence (AI) as key players look to adapt. Healthcare organizations around the world are turning to innovation within AI and machine learning space to help meet capacity challenges, accelerate the search for novel therapeutics, transition to telehealth, combat cyber threats and more. This panel will examine how academic-industry partnerships have and can continue to catalyze forging new frontiers in leveraging AI to improve healthcare delivery and management.